Genes Contributing to Pain Sensitivity in the Normal Population: An Exome Sequencing Study

Frances M. K. Williams, Serena Scollen, Dandan Cao, Yasin Memari, Craig L. Hyde, Baohong Zhang, Benjamin Sidders, Daniel Ziemek, Yujian Shi, Juliette Harris, Ian Harrow, Brian Dougherty, Anders Malarstig, Robert McEwen, Joel C. Stephens, Ketan Patel, Cristina Menni, So-Youn Shin, Dylan Hodgkiss, Gabriela Surdulescu, Wen He, Xin Jin, Stephen B. McMahon, Nicole Soranzo, Sally John, Jun Wang, Tim D. Spector

Abstract

Sensitivity to pain varies considerably between individuals and is known to be heritable. Increased sensitivity to experimental pain is a risk factor for developing chronic pain, a common and debilitating but poorly understood symptom. To understand mechanisms underlying pain sensitivity and to search for rare gene variants (MAF<5%) influencing pain sensitivity, we explored the genetic variation in individuals' responses to experimental pain. Quantitative sensory testing to heat pain was performed in 2,500 volunteers from TwinsUK (TUK): exome sequencing to a depth of 70× was carried out on DNA from singletons at the high and low ends of the heat pain sensitivity distribution in two separate subsamples. Thus in TUK1, 101 pain-sensitive and 102 pain-insensitive were examined, while in TUK2 there were 114 and 96 individuals respectively. A combination of methods was used to test the association between rare variants and pain sensitivity, and the function of the genes identified was explored using network analysis. Using causal reasoning analysis on the genes with different patterns of SNVs by pain sensitivity status, we observed a significant enrichment of variants in genes of the angiotensin pathway (Bonferroni corrected p = 3.8 × 10⁻⁴). This pathway is already implicated in animal models and human studies of pain, supporting the notion that it may provide fruitful new targets in pain management. The approach of sequencing extreme exome variation in normal individuals has provided important insights into gene networks mediating pain sensitivity in humans and will be applicable to other common complex traits.

Introduction

Chronic pain has a prevalence of nearly 20% in Europe [1] and similar estimates are reported for North America. The symptom is poorly controlled by existing therapies and the resulting personal and socio-economic burden is considerable. While many analgesic drugs are available, the vast majority of analgesic prescriptions are drawn from two classes of drug, opioids and nonsteroidal anti-inflammatory-like drugs, and have either limited efficacy or significant side effects. There is, therefore, a considerable need to develop novel analgesic treatments. The use of human genetics for identification of intrinsic factors that contribute to chronic pain states is attractive for several reasons. Chronic pain conditions as well as experimentally induced pain have been shown to have a considerable genetic component [2]. Twin studies have shown observed heritabilities of about 50% for different pain traits [3]. The manifestation of pain in response to experimental stimuli such as skin heating, or to clinical pathologies such as joint degeneration, is known to vary markedly. It is clear that a range of factors, including personality, expectation and mental state modulate the expression of chronic pain and these features are themselves genetically mediated. Modelling in twins, however, suggests that there are two separate predisposing genetic factors [4] including variants that modulate sensitivity to pain, as well as those mediating anxiety and depression. A number of approaches to pain sensitivity genetics have been adopted including the examination of rare (monogenic) syndromes of pain insensitivity (reviewed in [5]) and candidate genes identified from transcriptional profiling in animal models [6]. Candidate gene studies in humans with chronic pain have been unconvincing, and...
confirmed candidate gene associations are still lacking [reviewed in [4] and [7]]. The aim of the present study was to examine the influence of genetic variation, particularly rare variants having minor allele frequency <5%, on pain sensitivity in normal human volunteers. Two hypotheses were tested; that a single rare variant having large effect influences pain sensitivity and that the burden of variation would differ between sensitive and insensitive individuals.

Attempts to standardise and quantify pain sensibility in humans have led to the introduction of standardised thermal, mechanical or chemical stimuli that activate the nociceptive (pain signalling) system. Such quantitative sensory testing (QST) has been used to show that an individual’s sensitivity to experimental pain predicts risk of developing chronic pain after surgical interventions such as hernia repair [8] and arthroscopy [9]. That pre-operative pain sensitivity is a major risk factor for chronic post-operative pain [8] and insensitive) in the proportion of subjects harbouring rare variants; a difference in abundance of rare variants, weighted by function; and a multivariate difference in variant patterns between the two groups, allowing simultaneous excess in either pain group for any single rare variant within a gene.

We found no single rare variant to have a statistically significant association to heat sensitivity, after multiple testing correction. The strongest signal was found for GZMM, a serine protease from immune cell granules. However, our network analysis identified up to 30 genes harbouring rare SNVs as belonging to the Angiotensin II pathway, which has previously been linked to the pain phenotype in a number of settings.

Results

Singleton females were drawn from same sex twin pairs included in the sample so that gender- and relatedness bias were removed; after quality control all subjects were of north European descent. Complete data were available on 413 singleton subjects: TUK1 comprised 203 and TUK2 210 individuals. Analysis was performed in stages; TUK1, TUK2, combined TUK1 and TUK2 and pathway analysis. Details of the study participants are shown in Table 1. Based on the sample size required for exome sequencing and on the distributions obtained for HPT and HPST, insensitivity to heat pain was defined as HPST≥49.2°C, and sensitivity as HPST≤45.5°C. An individual designated insensitive/sensitive on HPST was included only if their HPT measure was higher/lower than the median HPT (46.6°C). The distributions of the TUK2 set were somewhat shifted, with median HPT = 46.0°C. Insensitivity to pain in TUK2 was defined as HPST> = 48.9°C while sensitivity was defined as HPST< = 45.4°C, with subjects required to have HPT above/below 46.0°C, respectively. Description of the exome sequencing findings in TUK1 and TUK2 groups is shown in Table S1. Details of the SNVs identified in the 2 datasets are shown in Table 2. The TUK2 set identified more variants of all types (except partial codons, which were extremely infrequent), which likely reflected the different exome capture arrays used and was consistent with greater coverage captured for the TUK2 set. However, the HapMap samples (n = 3) duplicated in the TUK1 and TUK2 exome sequencing showed no significant difference between number of SNVs called by the two platforms on commonly captured regions (by paired t-test, p = 0.24). The relative frequencies of the variants identified in the 2 datasets were compared to those recorded in dbSNP (http://www.ncbi.nlm.nih.

| Table 1. Characteristics of the individuals in the TUK1 and TUK2 samples. |
|-----------------|-----------------|-----------------|-----------------|
|                  | TUK1            | TUK2            |
| N total          | 203             | 210             |
| Age, years      | 60.11 (9.01)    | 56.50 (10.72)   |
| BMI, kg/m²      | 26.61 (5.07)    | 25.32 (4.15)    |
| Sensitive individuals |
| N               | 101             | 114             |
| HPT, C0         | 43.09 (2.47)    | 42.44 (2.32)    |
| HPST, C0        | 44.27 (1.10)    | 43.95 (1.54)    |
| Insensitive individuals |
| N               | 102             | 96              |
| HPT, C0         | 48.17 (0.72)    | 47.43 (0.98)    |
| HPST, C0        | 49.78 (0.28)    | 49.37 (0.41)    |

The mean (standard deviation) is shown for the TUK1 and TUK2 samples. N represents sample size; BMI, body mass index; HPT, heat pain threshold; HPST, heat pain suprathreshold.

doi:10.1371/journal.pgen.1003095.001
enrichment of rare variants (Figure S2).

sensitive groups, with the pain insensitive showing a relative
distribution of variants differed between the pain insensitive and
TUK2 analysis. Variants identified in
GZMM
heat pain sensitivity, \( p = 6.86 \times 10^{-5} \) in the combined TUK1 and
GZMM
insensitive to heat pain manifested rare variants more frequently
insensitive vs 4 alleles in the heat sensitive (\( p = 0.0016 \)). Individuals
test) in TUK1. While in TUK2 we found 17 alleles in the heat
Figure 2. For SNV A95T there were 12 alleles (1

Pathway analysis results

The 2nd lowest \( p \)-value among 6 gene-centric variant burden
tests was used as a cut-off to prioritise genes for pathway analysis
(see Methods, statistical analysis). After merging TUK1 and
TUK2 datasets, we identified 138 unique genes harbouring a rare
variant with a 2nd lowest \( p \)-value <0.01. First we examined the
functional annotations of these 138 genes using the online
functional annotation tool DAVID [http://david.abcc.ncifcrf.gov/]
[10]. Nine high level GO terms were nominally significantly
enriched in the gene list eg. “plasma membrane” and “intracellular
signalling cascade”. None reached significance after multiple
testing correction or offered obvious insights into mechanisms of
altered pain sensitivity (results not shown). We applied causal
reasoning to our data [11], which uses a large curated database of
directed regulatory molecular interactions to identify the most
plausible upstream regulators of a gene set. Of the 138 genes 86
were present in our database of causal interactions, from which we
identified 4 nominally significant regulatory networks (Table 4).

One of the regulatory networks, angiotensin II (Figure 3), was
highly enriched for a pain signal with 12 out of 204 genes in the
network also in the set of 86 genes with a nominal genetic burden.
This yields an odds ratio of 7.6, an enrichment \( p = 3.4 \times 10^{-6} \) and
a correctness \( p = 1.2 \times 10^{-3} \). Since 1108 pathways were tested, this
adjusts to enrichment \( p = 3.8 \times 10^{-4} \) and correctness \( p = 1.4 \times 10^{-5} \)
under multiple test correction.

We also investigated whether the genes identified were known
to interact physically with proteins playing a role in pain. For this
we used the BioGrid database of protein-protein interactions.
Notable connections included the binding of synaptotagmin-9
(SYT9), a membrane trafficking protein activated by calcium, to
TRPV1, the capsaicin receptor, which plays a key role in thermal
nociception [12]. The extracellular matrix glycoprotein laminin
B1 chain (LAMR1) interacts with the voltage dependent calcium
channel Cav2.1 (CAGNA1A) [13]. The receptor activity modifying
protein 3 (Ramp3) binds to the calcitonin receptor
(CALCRL), for transport to the membrane. Here the calcitonin
receptor recognises the calcitonin gene related peptide (CGRP), a
hormone proposed to contribute to pain transmission and
inflammation [14]. Finally, the sodium-hydrogen exchanger
regulatory factor 1 (SLC9AS1), binds the beta-2-adrenergic
receptor (ADRB2) [15], nitric oxide synthase 2 (NOS2) [16],
membrane metallo-endopeptidase (MME) [17] and the opioid
receptor kappa 1 (OPRK1) [18].

Discussion

Patients with chronic pain have increased sensitivity to noxious
stimuli such as heat and pressure compared to controls [19] as well
as to non-noxious stimuli such as sound [20]. These observations
support the notion that the processing of external stimuli is
heightened or exaggerated in chronic pain states. Thus, people
harbouring gene variants associated with greater sensitivity to heat
pain stimulus are thought to be at increased risk of developing
chronic widespread pain. The premise of this work was that
understanding better the genetic influence on normal pain
processing would shed light on the biological pathways underlying
the pathology of chronic pain. In this project we adopted novel
methods - biotechnological and statistical - to identify rare
sequence variation contributing to pain sensitivity in normal
individuals. The advent of high throughput genotyping technol-
ogies has helped to unravel the aetiology of many complex diseases
and quantitative traits. In particular, genome-wide association
(GWA) studies have uncovered many common variants associated
with quantitative phenotypes. However, GWA is underpowered to
detect association of rare variants, and the common variants
identified so far explain only a fraction of the trait heritability. As
whole-genome sequencing has become more cost-efficient it is now
feasible to examine the effect of rare variants. The hypothesis that
multiple rare variants explain a proportion of the missing
heritability is gaining more attention [21].

Rare variants with moderate to high penetrance have been associated with a number of extreme phenotypes [summarised in
[22]]. For quantitative phenotypes, sampling and comparing the
extremes of traits has become an accepted strategy for identifying
disease-causing rare variants in exome sequencing [23]. In this
novel exome project of pain perception in normal individuals, no
Figure 1. Quantile-quantile plots for the six different variant burden analysis methods. Quantile-quantile plots are shown for: (a) AMELIA, (b) CCRaVAT, (c) fixed filter test, minor allele frequency <0.05, (d) Madsen-Browning with polyphen weights, (e) Han and Pan aSumtest, (f) SSU, sum-of-squares test (Han and Pan).

doi:10.1371/journal.pgen.1003095.g001
genetic variants of large effect were identified. Considering that the statistical power after applying stringent multiple test correction was limited, we can’t exclude moderate or small contributions by individual SNVs to the experimental pain phenotype. Indeed, we have noted a differential distribution of rare variants between the pain sensitive and insensitive subjects (Figure S2), which suggests enrichment of multiple SNVs of small effect at the extremes of the normal distribution. This study also provides proof of principle of the utility of the exome sequencing method. Such an approach has been used successfully in the, albeit more limited, setting of sequencing ion channel genes in epilepsy [24]. The authors highlighted the need for cell and network analysis to optimise information obtained from such a study. A variety of statistical methods have been developed for analysis of association of rare variants with complex traits, but there remains a paucity of data regarding the genetic architecture underlying complex traits such as pain perception. For this reason we elected to use a variety of tests based on different underlying assumptions so that no rare variant associated with pain perception would be missed.

Table 3. Genes associated with heat pain sensitivity using six methods of gene-centric variant burden analysis.

| Gene     | List Source | Evidence category | Chr | Gene annotation                                      | Primary list 2nd lowest p-value | Merged 2nd lowest p-value |
|----------|-------------|-------------------|-----|-----------------------------------------------------|---------------------------------|---------------------------|
| GZMM     | Primary TUK1&2 | Very high         | 19  | granzyme M (lymphocyte met-ase 1)                    | 0.00010                         | 6.86 × 10⁻⁵⁵             |
| CCNJL    | Primary TUK1&2 | High              | 5   | cyclin J-like                                       | 0.00010                         | 0.00025                  |
| ZNF767*  | Primary TUK1&2 | High              | 7   | zinc finger family member 767                       | 0.00036                         | 0.00070                  |
| LAMA4    | Primary TUK1&2 | High              | 6   | laminin, alpha 4 [Homo sapiens]                     | 0.00041                         | 0.00117                  |
| OR5F1    | Primary TUK1&2 | High              | 11  | olfactory receptor, family 5, subfamily F, member   | 0.00074                         | 0.00033                  |
| TBK1     | Primary TUK1&2 | High              | 12  | TANK-binding kinase 1                               | 0.00083                         | 0.00030                  |
| DDAH1    | Primary TUK1&2 | High              | 1   | dimethylarginine dimethylaminohydrolase 1           | 0.00165                         | 0.00028                  |
| PDHA2    | Merged dataset | Medium            | 4   | pyruvate dehydrogenase (lipoamide) alpha 2          | -                               | 0.00060                  |
| FBXW7    | Merged dataset | Medium            | 4   | F-box and WD repeat domain containing 7             | -                               | 0.00063                  |
| DLD      | Merged dataset | Medium            | 7   | dihydrolipoamide dehydrogenase                      | -                               | 0.00078                  |
| RHEB     | Merged dataset | Medium            | 7   | Ras homolog enriched in brain                       | -                               | 0.00097                  |
| CCDC111  | Primary TUK1&2 | Medium            | 4   | coiled-coil domain containing 111                   | 0.00075                         | 0.00056                  |
| TAGAP    | Primary TUK1&2 | Medium            | 6   | T-cell activation RhoGTPase activating protein      | 0.00075                         | 0.00070                  |
| MYPN     | Primary TUK1&2 | Medium            | 10  | myopalladin                                         | 0.00149                         | 0.00095                  |

*represents known pseudogene; Chr chromosome.

“High” p < 0.00044 (based on p-value which reaches genome-wide significance if replicated, based on gene counts); “Very High” means “High” plus the merged data is more significant than by combining TUK1 and TUK2 p-values (implying synergy of direction); “Medium” is p < 0.001.

doi:10.1371/journal.pgen.1003095.003

GZMM was the only gene classified as having “very high” evidence of association to thermal nociception (Table 3 and Figure 2: see Methods: statistical analysis for classification definitions). It encodes granzyme M, one of the serine proteases produced and stored in the granules of immune cells such as lymphocytes and natural killer cells [25]. While we could not find reports of association with pain in the literature, granzymes are known to play an important role in apoptosis [26] and in the initiation of inflammation: elevated levels have been detected in rheumatoid synovial fluid [27] and granzyme B expression increased in lesional atopic dermatitis skin [28]. In the “high” evidence category, the enzyme encoded by the seventh gene, DDAH1, plays a role in nitric oxide generation by regulating cellular dimethylarginine concentrations, which in turn inhibit nitric oxide synthase. Although both anti-nociceptive and pro-nociceptive roles of NO have been reported, overproduction of NO – together with free radicals - contribute to central sensitisation and the pathogenesis of abnormal pain states via association with NMDA receptor mediated signalling events. In support of this, circulating NO has been shown to be elevated in chronic

Figure 2. SNVs identified in gene GZMM. Schematic showing number of subjects in TUK1 (top row) and TUK2 (bottom row) having nonsynonymous SNVs within the GZMM gene, with novel variants in black and those described in dbSNP in green. Subject counts in blue are for pain insensitive subjects and in red, pain sensitive. Squares represent homozygous and ovals heterozygous mutations. Exons are shown as dark cylinders, UTRs pale grey rectangles and introns dotted line.

doi:10.1371/journal.pgen.1003095.g002
Table 4. Pathways identified by causal reasoning.

| Pathway                      | Correctness p (Bonferroni corrected p) | Enrichment p (Bonferroni corrected p) | No. connections (no. possible connections) | Type of pathway |
|------------------------------|----------------------------------------|----------------------------------------|--------------------------------------------|-----------------|
| Angiotensin II –             | 1.2x10^-8 (1.4x10^-3)                  | 3.4x10^-7 (3.8x10^-4)                  | 12 (204)                                   | Peptide         |
| Estrogen –                   | 0.001 (>1)                             | 0.002 (>1)                             | 3 (26)                                     | Biological process |
| Adipocyte differentiation –  | 0.004 (>1)                             | 0.005 (>1)                             | 4 (76)                                     | Biological process |
| Triamcinolone acetonide +    | 0.04 (>1)                              | 0.01 (>1)                              | 3 (94)                                     | Chemical        |

Causal reasoning [11] uses a large curated database of directed regulatory molecular interactions to identify the most plausible upstream regulators of a gene set with a proposed directionality (eg. down-regulated). We considered the 138 genes identified to contain loss of function mutations. One regulatory pathway (angiotensin II) is significant after correction for multiple testing when considering directionality (Correctness p) as well as when ignoring directionality of regulation (Enrichment p). The sign (-/+e) after the regulator's name indicates the loss (-) or gain (+) of activity required to explain the loss of function mutations. Enrichment p-value indicates the significance of the number of connections apparent in our data compared to the total number of connections. Correctness p-value also accounts for the regulatory direction (+/-e) and indicates the significance of the hypothesis as a regulator.

doi:10.1371/journal.pgen.1003095.t004

Figure 3. The Angiotensin II regulatory network was identified by causal reasoning from 138 genes associated with pain sensitivity. Causal reasoning uses directed molecular interactions to work upstream from the genes in this study (green) to identify regulators such as angiotensin II (blue) that have a causally correct regulatory role for a significant number of input genes. Correctness is determined by giving each input gene a direction of effect. Here, we presumed a loss of function (e.g. down regulation in activity) to all of our genes. Angiotensin II has direct causal connections to 12 of the genes from our 138, which can be increased to 30 if one intermediary node is allowed in the network (Figure S1). Distribution of novel rare variants identified according to minor allele frequency in a) TUK1 and b) TUK2 datasets.

doi:10.1371/journal.pgen.1003095.g003
opioid receptor. It is clear therefore that although we did not identify any genes immediately associated with nociception, several play key roles in processes linked to the reception and transduction of pain signals by their physical and biochemical interactions with important pain mediating complexes.

This study highlights the potential of using a combination of sophisticated analytical methods to identify associations underlying rare variants in quantitative traits. While the predicted effect sizes are relatively small and require large samples, we have made progress in understanding the genetic architecture underlying heat pain sensitivity. Despite recent advances in both DNA sequencing technology and the statistical methods to analyse such complex datasets, the identification and follow-up of associations of individual gene variants remains a challenge. Our results lend weight to the notion that angiotensin II plays an important role in several key pain signalling complexes.

Materials and Methods

Ethics committee approval was obtained from Guy’s and St Thomas’ Hospital research ethics committee. All subjects were volunteer singleton members of female monozygotic (MZ) and dizygotic (DZ) twins from the TwinsUK register of King’s College London [37]. Thus we did not perform a classical twin study and did not need to adjust for relatedness. QST was performed according to standard methods (see Supporting information) in all twins with an intra-class correlation coefficient of 0.29. The two phenotypes were correlated ($r = 0.64$). To provide in Text S1.

Selection for exome sequencing

HPST score was selected as the primary metric because reproducibility was greater (intra-class correlation coefficients, HPST = 0.59 (0.51, 0.68); HPT = 0.34 (0.23, 0.46)). HPST was also found to have greater heritability (HPST $h^2 = 0.44$; HPT $h^2 = 0.29$). The two phenotypes were correlated ($r = 0.64$). To select subjects who were relatively pain sensitive/insensitive for signal transduction in pain and this pathway merits further biological investigation.

Exome sequencing

DNA extracted from whole blood was sent to BGI for exome sequencing [38]. The qualified genomic DNA sample was randomly fragmented by Covaris technology with resultant library fragments 250–300 bp. Adapters were ligated to both ends of the fragments. Extracted DNA was amplified by ligation-mediated PCR (LM-PCR), purified and hybridized to the NimbleGen human exome arrays for enrichment; non-hybridized fragments were then washed out. The target enrichment of the TUK1 samples were performed using hybridization to the NimbleGen 2.1 M array, while the shotgun libraries of the TUK2 samples were enriched using NimbleGen EZ v2 library. The captured LM-PCR products were subjected to quantitative PCR to estimate the magnitude of enrichment. Each captured library was then loaded on Illumina platforms and high-throughput sequencing was performed on each library. The BGI used Illumina GAIIx for sequencing of the TUK1 samples and a HiSeq2000 platform for TUK2 samples. Raw image files were processed by Illumina base-calling software v1.6 (and v1.7), and the sequences of each individual were generated as 75 bp (and 90 bp) paired-end reads for TUK1 (and TUK2) sets respectively. The fastq files were generated from the raw data after removing the adapters and low quality reads.

Exome mapping

Both datasets were mapped to the NCBI Human Reference (GRCh37; hg19) using BWA v0.5.5 (v0.5.9). We considered the default parameter -q 15 for read clipping, and a maximum insert size of 600 bp for proper pairing of the short reads. The alignment files for each lane were sorted and indexed by SAMtools [39] before constructing the library-level bam files. We also tried to improve the accuracy of the base quality scores by running a recalibration stage using Genome Analysis Toolkit (GATK) v1.0.5777 [40]. On average 5% of each library was contaminated with duplicate fragments, which were removed before variant calling. An extra step of local re-alignment was applied only to the TUK2 data to improve the sensitivity and specificity of mismatches near indel sites.

For quality control (QC) of the TUK1 data, we studied the histogram of depth distribution, the distribution of inferred insert sizes in the bam files, the GC content distribution for reads mapped to forward and reverse strands, the depth of coverage as a function of percentile of unique sequences ordered by GC content, and the fraction of each chromosome covered by the exomes. The distribution of per-base sequencing depth for each sample was evaluated as was the cumulative depth distributions in target regions, and sequencing depth and coverage of the target region per chromosome. The TUK2 dataset had a slightly higher depth of coverage over the capture target region (CTR, with average 71x depth (compared to 69x for TUK1), whereas average coverage of the CTR was 97.5% for TUK2 (compared to 96.5% in TUK1). In the TUK1 panel we discarded and re-sequenced a few lanes, which showed very low target coverage; hence requiring all the exomes to cover more than 70% of the CTR by at least 20x in both datasets. We observed that although the mean depth was comparable, the fraction of CTR covered at a given depth was generally lower in TUK2 set, e.g. CTR coverage at ≥20x was 80.3% for TUK2 compared to 89.1% for TUK1. This alludes to the greater coverage uniformity of the 2.1 M array compared with that of the solution-based EZ sequence capture.

Variant calling

For TUK1, we ran SAMtools v0.1.8 ‘pileup’ while limiting maximum depth for indels to 500. Then we filtered the SNVs with ‘varFilter’ with SNV and indel Phred-scale quality scores less than 20, and minimum and maximum depth at 8 and 300 respectively. The GATK v1.0.5777 was run for TUK1 using default values and a minimum confidence threshold 30 and respectively. The GATK calling for TUK2 datasets had a slightly higher depth of coverage over the capture target region (CTR), with average 71x depth (compared to 69x for TUK1), whereas average coverage of the CTR was 97.5% for TUK2 (compared to 96.5% in TUK1). In the TUK1 panel we discarded and re-sequenced a few lanes, which showed very low target coverage; hence requiring all the exomes to cover more than 70% of the CTR by at least 20x in both datasets. We observed that although the mean depth was comparable, the fraction of CTR covered at a given depth was generally lower in TUK2 set, e.g. CTR coverage at ≥20x was 80.3% for TUK2 compared to 89.1% for TUK1. This alludes to the greater coverage uniformity of the 2.1 M array compared with that of the solution-based EZ sequence capture.

Variant calling

For TUK1, we ran SAMtools v0.1.8 ‘pileup’ while limiting maximum depth for indels to 500. Then we filtered the SNVs with ‘varFilter’ with SNV and indel Phred-scale quality scores less than 20, and minimum and maximum depth at 8 and 300 respectively. The GATK v1.0.5777 was run for TUK1 using default values and a minimum confidence threshold 30 and minimum read mapping quality at 10. We subsequently filtered the GATK SNVs by keeping only those with alternative allele quality score ≥ 20 and depth within [8,300] interval. For TUK2, we ran SAMtools v0.1.16 ‘pileup’ together with ‘bcf tools’ using default parameters, but requiring the SNV quality score and depth interval to satisfy the same criteria of the TUK1 set (i.e. QUAL≥20 and 300≥DP≥8). The GATK calling for TUK2 data followed the same procedure as for TUK1. We further filtered all the variants outside the capture target region. Overlapping results SAMtools and GATK were extracted. The discordance (about 5%) was largely attributed to unique calls, however we observed a small fraction (less than 1%) of SNVs
called by both algorithms were assigned mismatching genotypes (homozygous non-reference vs heterozygous). We ran the GATK on the coordinates of the overlap to determine the non-variant genotypes hence adjusting the missing rates. The single-sample variant files were then merged (using ‘merge-vcf’) into two large variant call files (VCF) each containing the entire sample variants. Table S1 compares the SNV statistics for TUK1 and TUK2 samples.

Genotype QC

We evaluated the genotype concordance between the exome and pre-existing GWAS datasets. We observed greater agreement between GWAS and TUK2 (average 99.8%) than GWAS and TUK1 (99.3% concordance) (Table S1). Three samples were identified as highly discordant with GWAS (52%, 54% and 51% rates). A multi-dimensional clustering analysis of these three exomes together with the entire GWAS dataset for 5,654 twins, confirmed that they were true outliers so were excluded from statistical analysis. Duplicate samples in TUK1 allowed estimation of genotype error rate. Out of ~35 M bases on the 2.1 M array which had been genotyped, 295 and 374 sites were discordant between duplicates. This sets a type 1 error rate for genotyping of approximately 1.0e-05, or 0.001%.

Statistical analysis

The wide variety of methods to analyse rare variants generally fall into three broad categories: “collapsing” methods, which test for differences in rare variant accumulation; “carrier-based” tests, which test for differences in the number of subjects carrying a certain class of variant (usually at least partially based on frequency thresholds); and “multivariate” tests, which test for differences in variant patterns, and is further subdivided into kernel-based and regression-based methods. Using several tests from each category we ran 21 different gene-centric variant burden tests on the TUK1 set and the results correlated (and displayed as a “heat” map, Table S2). A pair of tests was selected from each category/correlation block based on the correlation matrix and the QQ plots (Figure 1). The six statistical methods selected for this project were:-

- AMELIA: Allele Matching Empirical Locus-specific Integrat-ed Association test. Multivariate test considering both common and rare variants, and is based on genotypic similarity rather than rare allele accumulation [41]
- aSum: Data adaptive sum test. A regression based collapsing approach, which takes account of the direction of effect of the alleles. This type of method is expected to tolerate misclassification eg. if alleles with different functions are collapsed together [42]
- SSU (Sum of Squares Test): a test analogous to traditional multivariate analysis on a binary trait [42]
- simple threshold test: a case/control by subject on carriers with one or more variants having MAF<0.05. It is similar to the CAST method [43]
- CCRaVAT (using Pearson test): collapsing method examining the accumulation of rare alleles using analysis of contingency tables. Like ARIEL, it is sensitive to linkage disequilibrium, however it evaluates the presence or absence of individual rare alleles in cases or controls (rather than the proportion rare variants) [44]
- Madsen and Browning using polyphen weights (MB pphen): method combines variants by weighting based on allele frequency and, optionally, polyphen predictions (selected here) [45]

A primary list of genes harbouring rare variants was drawn up based on combining the p-values from TUK1 and TUK2 sets using Fisher’s method. To identify signals from genes with concordant variant patterns across TUK1 and TUK2 datasets, the top genes from the merged raw TUK1 and TUK2 datasets were also considered as relevant signals. This combination did not comprise the primary list because the TUK1 and TUK2 sequencing were performed on different capture platforms: some regions did not overlap between the two. Further details are provided in Supporting information.

In addition to the issue of combining TUK1 and TUK2 was the challenge of combining and sorting the results of the 6 gene-centric variant burden tests which were relatively new and not well understood. Because the 6 tests comprised 3 pairs of similar test methods (Table S2) we considered that a result was not robust if it was significant for only 1 test category. Significance in more than 1 category added confidence that a result was less likely to be a false signal. To prioritize genes that were either significant in more than one category or consistently significant for both tests within a pair, we prioritized genes based on the 2nd lowest p-value from the 6 selected tests. This approach also ensured that the top gene list could not be dominated by anomalies from a single test. Significant results using the 2nd lowest p-value were obtained in two ways: from combining the TUK1 and TUK2 p-values via Fisher’s formula, and by merging the datasets (Table 3). A gene was classified as “High” evidence if its 2nd lowest p-value achieved p<0.00044 (the p-value such that replication would achieve a genome-wide significant meta-analytic p-value), and “Very High” if this occurred with the combined dataset being more significant than the combination of the p-values across the two halves. “Medium” priority was given any gene which achieved p<0.001 for its 2nd lowest p-value in either the merged dataset or the combination of the p-values across the two halves.

Pathway analysis

After removing genes showing an opposite direction of effect and after merging the datasets, we identified 138 unique genes having a 2nd lowest p-value<0.01. These were considered for more detailed analysis. We looked first for enriched Gene Ontology categories within these genes using DAVID [10] with an EASE p-value<0.05. Then we undertook causal reasoning [11] which uses a large curated database of directed regulatory molecular interactions to identify the most plausible upstream regulators of a gene set. Consequently it allows the recapitulation of regulatory networks/pathways associated with genes of interest. The method offers two measures of statistical significance. The enrichment p-value corresponds to a standard gene set enrichment test on the set of downstream genes, whereas the correctness p-value takes the direction of regulation into account. For the latter, each associated gene was considered as a down-regulated transcript in the causal reasoning network i.e. assumed loss-of-function mutations. As a background set for the significance calculations we considered the intersection of the set of all genes covered in either the TUK1 or TUK2 study and all transcripts in our causal reasoning database. This set consists of 9275 genes. A regulatory hypothesis was considered nominally significant with a p-value<0.05 and significant at a 0.05 level after application of the Bonferroni correction for multiple testing. As we are considering 1108 potential upstream regulators in the underlying database, a Bonferroni corrected p of 0.05 corresponds to a nominal p-value of 4.5×10^-7. Finally, we searched for direct physical interactions

Single Nucleotide Variants in Pain Sensitivity
between proteins identified in this study and proteins known to have a role in pain using protein interaction data from the BioGrid database [46].

Supporting Information

Figure S1 Relative proportions of novel and recognised variants in the two samples. Recognised variants were defined by their presence in dbSNP. Data are shown by allele frequency (y axis) for (a) TUK1 dataset and (b) TUK2 dataset.

(TIF)

Figure S2 Relative frequencies of novel rare variants detected, by pain sensitivity. The frequency distribution of non-synonymous genes had at least 10% difference in rare variant counts differing by gene. There remained a small excess of variants in pain sensitive: pain sensitive variant counts were 0.51 (95% CI: 0.272–0.962) that of the insensitive. As such a finding could result from a few one-sided genes we also adjusted for variant excess differing by gene. There remained a small excess of variants in pain insensitive individuals across all genes, p = 0.033. Seventeen genes had at least 10% difference in rare variant counts (MAF<0.05) between the sensitive and insensitive subjects. Of these 17 genes, 14 had excess insensitive variants, while only 3 had the excess sensitive subjects (p = 0.0127 for 2-sided t-test).

(TIF)

Table S1 Details of exome sequencing. Descriptive statistics for variants identified in exome sequencing of TUK1 and TUK2 sample sets. The values were generated from filtered variants for all samples which passed QC.

(DOCX)

Table S2 Relationship between the 21 rare variants analysis methods used in the TUK1. Heat Map or correlation matrix of the −log10 p values (pval) for each pair of 21 methods run in TUK1. Higher correlations are colored red, lower correlations are colored blue. The 6 tests selected for use in the study are marked in italics and underlined. The full set of 21 analytical methods are as follows: KBAT represents kernel based association test; AMELIA, Allele Matching Empirical Locus-Specific Integrated Association; ARIEL, Accumulation of Rare variants Integrated and Extended Locus-specific test; CCRaVAT, Case-Control Rare Variant Analysis Tool; FishExc, Fisher’s exact test; pval maf 0.01, p value of fixed threshold test with minor allele frequency <0.01; MB, Madsen and Browning weighted approach; VT, variable threshold; pphen, Polyphen; SSU, sum of squared test; aSum permut, Han and Pan’s aSum test permutated; aSum, Han and Pan’s aSum test.

(DOCX)

Text S1 Further details are provided regarding the subjects and their selection, the quantitative sensory testing, and rare variant analysis.

(DOCX)

Acknowledgments

Our thanks to Gordon McMurray, Rie Suzuki, and Peter J Cox of Neurens for their help in understanding the function of genes identified in this study, also to Eleftheria Zeggini and Jennifer Anmit of Wellcome Trust Sanger Institute for their input into the gene-centric variant burden analysis, in particular allowing access to ARIEL and AMELIA pre-publication.

Author Contributions

Conceived and designed the experiments: SJ TDS FMKW SS CLH BD IH NS SBM. Performed the experiments: YS XJ JW JH GS DH FMKW RM. Analyzed the data: YS NS CLH BZ DZ BS JCS KP CM S-YS. Contributed reagents/materials/analysis tools: YS XJ JW JH GS DH FMKW SA. Wrote the paper: FMKW SS CLH YM BZ TDS SJ AM JCS SBM.

References

1. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D (2006) Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 10: 297–333.
2. Kato K, Sullivan PF, Evergand B, Pedersen NL (2006) Importance of genetic influences on chronic widespread pain. Arthritis Rheum 54: 1082–1086.
3. Norbury TA, MacGregor AJ, Urwin J, Spector TD, McMahon SB (2007) Heritability of responses to painful stimuli in women: a classical twin study. Brain 130: 3041–3049.
4. Schmidt-Wäcke T, Clauw DJ (2011) Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol 7: 518–527.
5. Macefield VG (2009) Developments in autonomic research: a review of the latest literature. Clin Auton Res 19: 193–196.
6. LaCroix-Fralish ML, Austin JS, Zheng FY, Levitin DJ, Mogil JS (2011) Patterns of pain: meta-analysis of microarray studies of pain. Pain 152: 1081–1091.
7. Young EE, Lariviere WR, Belfer I (2012) Genetic basis of pain variability: recent advances. J Med Genet 49: 1–9.
8. Aasvang EG, Gnaeule H, Hansen JB, Gnaeule B, Forman JH, et al. (2010) Predictive risk factors for persistent postherpetic pain. Anesthesiology 112: 957–969.
9. Werner MU, Duun P, Kehlet H (2004) Prediction of postoperative pain by preoperative nociceptive responses to heat stimulation. Anesthesiology 100: 115–119; discussion 11A.
10. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57.
11. Chindelevitch L, Macgregor AJ, Ulrich J, Spector TD, McMahon SB (2007) Heritability of responses to painful stimuli in women: a classical twin study. Brain 130: 3041–3049.
12. Kato K, Sullivan PF, Evergand B, Pedersen NL (2006) Importance of genetic influences on chronic widespread pain. Arthritis Rheum 54: 1082–1086.
13. Norbury TA, MacGregor AJ, Urwin J, Spector TD, McMahon SB (2007) Heritability of responses to painful stimuli in women: a classical twin study. Brain 130: 3041–3049.
14. Hlaiiret S, Fooed SM, Marshall FH, Bourier M (2001) Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calceiton receptor-like receptor and the receptor activity-modifying proteins. J Biol Chem 276: 29573–29581.
15. Hall RA, Przemont RT, Choe CM, Bitzer JT, Picher JA, et al. (1998) The beta2-adrenergic receptor interacts with the Na+/H+ exchanger regulatory factor to control Na+/H+ exchange. Nature 392: 626–630.
16. Glyme PA, Darling KE, Picot J, Evans TJ (2002) Epithelial membrane nitric-oxide synthase is an apical EBPs50-binding protein that directs vescicular nitric oxide output. J Biol Chem 277: 33132–33139.
17. Dell’Era MA, Oudes A, Martin DB, Liu AY (2007) HSP27 and HSP70 interact with CD10 in C4-2 prostate cancer cells. Prostate 67: 714–721.
18. Huang P, Steplock D, Weisman EJ, Hall RA, Ding Z, et al. (2004) kappa Opioid receptor interacts with Na+/H+/exchanger regulatory factor-1/Erbin-rasuxiniosin-binding phosphoprotein-50 (NHERF-1/EBP50) to stimulate Na+/H+ exchange independent of G(i)/G(o) proteins. J Biol Chem 279: 25002–25009.
19. Peles MR, Casey KL, Bruckach CB, Ribbens CM, Appleton BB, et al. (2003) Perception of noxious and innocuous heat stimulation among healthy women and women with fibromyalgia: association with mood, somatic focus, and catastrophizing. Pain 102: 243–250.
20. Geiser ME, Glass JM, Rajcevica LD, Clauw DJ, Williams DA, et al. (2008) A psychophysical study of auditory and pressure sensitivity in patients with fibromyalgia and healthy controls. J Pain 9: 417–422.
21. Singleton AB (2011) Exome sequencing: a transformative technology. Lancet Neurol 10: 942–946.
22. Ng SB, Nickerson DA, Bamshad MJ, Shendure J, et al. (2006) Variation in the human genome. Science 316: 1299–1301.
25. de Koning PJ, Kummer JA, Beverschen N (2009) Biology of granzyme M: a serine protease with unique features. Crit Rev Immunol 29: 307–315.
26. Chowdhury D, Lieberman J (2008) Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol 26: 309–420.
27. Tak PP, Spaeny-Dekking L, Kraan MC, Breedveld FC, Frolich CJ, et al. (1999) The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol 116: 366–370.
28. Yawalkar N, Schmidt S, Braathen LR, Fischer WJ (2001) Perforin and granzyme B may contribute to skin inflammation in atopic dermatitis and psoriasis. Br J Dermatol 144: 1133–1139.
29. Koch A, Zacharowski K, Boehm O, Stevens M, Lipfert P, et al. (2007) Nitric oxide and pro-inflammatory cytokines correlate with pain intensity in chronic pain patients. Inflamm Res 56: 32–37.
30. Chindleveitch I, Ziemek D, Enayetallah A, Randhawa R, Sidders B, et al. (2012) Causal reasoning on biological networks: interpreting transcriptional changes. Bioinformatics 28: 1114–1121.
31. Marques-Lopes J, Pinto M, Paio D, Morato M, Painha D, et al. (2009) Microinjection of angiotensin II in the caudal ventrolateral medulla induces hyperalgesia. Neuroscience 158: 1301–1310.
32. Jaggi AS, Singh N (2011) Exploring the potential of telmisartan in chronic constriction injury-induced neuropathic pain in rats. Eur J Pharmacol 667: 215–221.
33. Kalra J, Chaturvedi A, Kalra S, Chaturvedi H, Dhasmana DC (2008) Modulation of pain perception by ramipril and losartan in human volunteers. Indian J Physiol Pharmacol 52: 91–96.
34. Guasti L, Zanotta D, Diebbi A, Garganico D, Simonc C, et al. (2002) Changes in pain perception during treatment with angiotensin converting enzyme-inhibitors and angiotensin II type 1 receptor blockade. J Hypertens 20: 485–491.
35. Hu ZW, Kerb R, Shi XY, Wei-Lavery T, Hoffman BB (2002) Angiotensin II increases expression of cyclooxygenase-2: implications for the function of vascular smooth muscle cells. J Pharmacol Exp Ther 303: 563–573.
36. England S, Bevan S, Docherty RJ (1996) PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade. J Physiol 495 (Pt 2): 429–440.
37. Spector TD, Williams FM (2006) The UK Adult Twin Registry (TwinsUK). TwinResHumGenet 9: 899–906.
38. Metzger ML (2010) Sequencing technologies - the next generation. Nat Rev Genet 11: 31–46.
39. Li H, Handsaker B, Wysocker A, Fennell T, Ruan J, et al. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078–2079.
40. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, et al. (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43: 491–498.
41. Zeggini E, Asimit JL (2011) An evaluation of power to detect low-frequency variant associations using allele-matching tests that account for uncertainty. Pac Symp Biocomput: 100–105.
42. Han F, Pan W (2010) A data-adaptive sum test for disease association with multiple common or rare variants. Hum Hered 70: 42–54.
43. Cohen JC, Kus RS, Perperihidius A, Marcel YL, McPherson R, et al. (2004) Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305: 869–872.
44. Lango AH, Estrada K, Lettre G, Berndt SI, Weedon MN, et al. (2010) Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467: 832–838.
45. Price AL, Kryukov GV, de Bakker PI, Purcell SM, Staples J, et al. (2010) Pooled association tests for rare variants in exen-resequencing studies. Am J Hum Genet 86: 632–838.
46. Stark C, Birkkreutz BJ, Reguly T, Boucher L, Birkkreutz A, et al. (2006) BioGRID: a general repository for interaction datasets. Nucleic Acids Res 34: D535–539.